According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), InMed Pharmaceuticals Inc (INM) officially confirmed and passed a resolution on March 4 to gradually terminate the commercial operations of its Baymedica division.

According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), InMed Pharmaceuticals Inc (INM) officially confirmed and passed a resolution on March 4 to gradually terminate the commercial operations of its Baymedica division.

老虎证券2026/03/06 22:31

Show original

This decision marks a strategic shift for the company, with future resources to be more focused on core business areas.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), InMed Pharmaceuticals Inc (INM) officially confirmed and passed a resolution on March 4 to gradually terminate the commercial operations of its Baymedica division.

You may also like

Trending news

Crypto prices